Ocular Therapeutix (OCUL) Operating Expenses (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Operating Expenses of $95.6 million for Q2 2026, up 17.86% year-over-year from $81.1 million in Q2 2025, and down 8.2% on a QoQ basis from $104.1 million in Q1 2026.
Ocular Therapeutix (OCUL) Operating Expenses (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Operating Expenses for 14 years, with the latest figure at $95.6 million in Q2 2026.
- Operating Expenses for Q2 2026 came in at $95.6 million, up 17.86% year-over-year; the trailing twelve-month figure through Jun 2026 was $366.0 million (up 28.5% YoY), and the FY2025 annual result was $322.0 million, up 36.71% from the prior year.
- Operating Expenses retreated to $95.6 million in Q2 2026, from $104.1 million in the prior quarter.
- Over five years, Operating Expenses peaked at $104.1 million in Q1 2026 and troughed at $31.0 million in Q1 2022.
- A 5-year average of $57.1 million and a median of $53.2 million in 2024 frame the typical range for Operating Expenses.
- The widest annual swing landed in 2022, when Operating Expenses climbed 0.73%; it then jumped 94.14% in 2024.
- A 5-year view of Operating Expenses shows it stood at $33.4 million in 2022, then rose by 4.23% to $34.9 million in 2023, then surged by 94.14% to $67.7 million in 2024, then increased by 22.69% to $83.0 million in 2025, then gained by 15.15% to $95.6 million in 2026.
- Per Business Quant data, the three most recent Operating Expenses figures were $95.6 million in Q2 2026, $104.1 million in Q1 2026, and $83.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 95.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 95.58 Mn |
| Mar 31, 2026 | 104.13 Mn |
| Dec 31, 2025 | 83.01 Mn |
| Sep 30, 2025 | 83.24 Mn |
| Jun 30, 2025 | 81.10 Mn |
| Mar 31, 2025 | 74.62 Mn |
| Dec 31, 2024 | 67.66 Mn |
| Sep 30, 2024 | 61.42 Mn |
| Jun 30, 2024 | 60.03 Mn |
| Mar 31, 2024 | 46.39 Mn |
| Dec 31, 2023 | 34.85 Mn |
| Sep 30, 2023 | 34.30 Mn |
| Jun 30, 2023 | 35.76 Mn |
| Mar 31, 2023 | 35.92 Mn |
| Dec 31, 2022 | 33.44 Mn |
| Sep 30, 2022 | 33.51 Mn |
| Jun 30, 2022 | 32.18 Mn |
| Mar 31, 2022 | 31.02 Mn |
| Dec 31, 2021 | 30.36 Mn |
| Sep 30, 2021 | 31.68 Mn |